These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20023901)

  • 1. A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity.
    van Rijn JA; Marqués-Gallego P; Reedijk J; Lutz M; Spek AL; Bouwman E
    Dalton Trans; 2009 Dec; (48):10727-30. PubMed ID: 20023901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.
    Ochocki J; Kasprzak M; Chęcińska L; Erxleben A; Zyner E; Szmigiero L; Garza-Ortiz A; Reedijk J
    Dalton Trans; 2010 Oct; 39(40):9711-8. PubMed ID: 20830400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
    Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
    Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual anti-angiogenic and cytotoxic properties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands.
    Sun RW; Ng MF; Wong EL; Zhang J; Chui SS; Shek L; Lau TC; Che CM
    Dalton Trans; 2009 Dec; (48):10712-6. PubMed ID: 20023898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A straightforward and generalizable synthetic methodology for the synthesis of ruthenium(II) complexes with thioether ligands from either Ru(III) or Ru(0) precursors.
    Maiti BK; Görls H; Klobes O; Imhof W
    Dalton Trans; 2010 Jun; 39(24):5713-20. PubMed ID: 20495720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
    Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
    Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
    Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
    Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
    Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
    Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(iii) complexes with bulky triazolopyrimidine ligands.
    Łakomska I; Fandzloch M; Muzioł T; Lis T; Jezierska J
    Dalton Trans; 2013 May; 42(17):6219-26. PubMed ID: 23328694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA): cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands.
    Porchia M; Benetollo F; Refosco F; Tisato F; Marzano C; Gandin V
    J Inorg Biochem; 2009 Dec; 103(12):1644-51. PubMed ID: 19822369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
    Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
    Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel half-sandwich Ru(II)-hydroxamate complexes: synthesis, characterization and equilibrium study in aqueous solution.
    Buglyó P; Farkas E
    Dalton Trans; 2009 Oct; (38):8063-70. PubMed ID: 19771370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
    Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
    Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.
    Nagy EM; Nardon C; Giovagnini L; Marchiò L; Trevisan A; Fregona D
    Dalton Trans; 2011 Nov; 40(44):11885-95. PubMed ID: 21971872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on potential antitumor mechanism of a novel Schiff base copper(II) complex: synthesis, crystal structure, DNA binding, cytotoxicity and apoptosis induction activity.
    Qiao X; Ma ZY; Xie CZ; Xue F; Zhang YW; Xu JY; Qiang ZY; Lou JS; Chen GJ; Yan SP
    J Inorg Biochem; 2011 May; 105(5):728-37. PubMed ID: 21463568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
    Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruthenium polypyridine complexes of tris-(2-pyridyl)-1,3,5-triazine-unusual building blocks for the synthesis of photochemical molecular devices.
    Schwalbe M; Karnahl M; Görls H; Chartrand D; Laverdiere F; Hanan GS; Tschierlei S; Dietzek B; Schmitt M; Popp J; Vos JG; Rau S
    Dalton Trans; 2009 May; (20):4012-22. PubMed ID: 19440601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.